retatrutide clinical trial phase ESC 2024: improves lipid and cardiovascular risk profile in II retatrutide clinical trial dosing retatrutide

L., Montesi, L., Colosimo, S., Caletti, M

[DOI] [PubMed] [Google Scholar] 188.Giuse N.B., Koonce T.Y., Kusnoor S.V., Prather A.A., Gottlieb L.M., Huang L.C., Phillips S.E., Shyr Y., Adler N.E., Stead W.W

It belongs to the same broad family as semaglutide and tirzepatide, but goes a step further: it acts on three hormone receptors at once

The most common side effects of GLP-1 injections are gastrointestinal: nausea, vomiting, diarrhea, and constipation

Neither medication is currently available in Canada through traditional channels, though Mazdutide has already received regulatory approval in China and sits closer to global market availability

Early weight loss includes significant water as glycogen stores deplete and sodium intake typically decreases